Frost & Sullivan: iRegene Therapeutics Honored as '2025 Forbes China Leading Enterprises in Industry Development'
Recently, The '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor,' jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund.
Amid the global trend of industrial innovation, the results of the '2025 Pioneer Innovators in Industry Development' selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies.
iRegene Therapeutics Honored as [2025 Forbes China Leading Enterprises in Industry Development]
Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala.
AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy
Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases.
iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the 'AI+Chem' platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies.
With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial.
In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, brings strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy.
To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene – Danaher Joint Innovation Center, which is the world's first 'Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems'. The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research.
iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression.
About iRegene Therapeutics
iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine — making advanced therapies accessible to patients worldwide.
In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024.
Media Contact
Company Name: Frost & Sullivan
Contact Person: Qian Li
Email: Send Email
Country: China
Website: http://www.frostchina.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Point B launches innovation centre in US for restaurant operators
Management consultancy Point B has opened its Restaurant Technology Innovation Center in Chicago, Illinois, to assist operators by providing a practical resource. The fully integrated technology ecosystem of the facility provides restaurant operators with an understanding of how platforms can enhance operations and customer experiences. It features commerce platforms, kitchen displays, back-office systems, kiosks, tipping systems, loyalty programmes, digital menu and order confirmation boards, and AI. The centre utilises the latest technologies in a live environment for different restaurant concepts such as quick service, table service and fast casual. It also provides customised workshops tailored to address operational and technology challenges faced by restaurant brands. Point B's comprehensive restaurant tech stack offering through the centre is designed to support multi-unit restaurants in their quest to transform their technology infrastructure. Intended outcomes include boosting average unit volumes, scaling for growth, simplifying operations, serving more guests, gaining data insights and improving service speed. Point B CEO David Hanfland stated: 'Multi-unit restaurant operators have an overwhelming number of options to evaluate before investing in new technology. 'To make these decisions easier, Point B's Restaurant Technology Innovation Center provides a centralised hub showcasing the leading technology solutions so they can try them before implementation.' It is a hub for practical application, where restaurants can redefine their operations and achieve sustainable growth. Point B restaurant industry senior client partner Rich Faltot stated: 'This is more than just a lab — it's a strategic ecosystem designed to help restaurants innovate with confidence. 'By simulating real-world scenarios using enterprise-grade technology, we're giving brands the clarity and tools they need to drive performance, avoid missteps and lead the industry forward.' "Point B launches innovation centre in US for restaurant operators" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Entrepreneur
an hour ago
- Entrepreneur
Campus Fund Launches USD 100 Mn Fund to Back Student Led Startups
Fund III plans to support up to 60 startups over the next four years, with initial investments ranging from INR 1 crore to INR 8 crore. Half of the fund is reserved for follow-on investments. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Campus Fund, a venture capital firm dedicated to student and dropout-led startups, has announced its largest fund to date—USD 100 million third fund. The firm has already secured more than half of the capital in its first close and has begun deploying funds, with two investments already finalised. Founded by Richa Bajpai in 2020 as a thesis project at London Business School, Campus Fund exclusively supports founders who are currently in university, have dropped out, or graduated within the last three years. Registered as a Sebi Category II Alternative Investment Fund (AIF), it evaluates over 7,000 startups annually through a network of more than 100 student scouts. "This is a full-circle moment for me," said Bajpai, who also co-founded Goodera. "My entrepreneurial journey started in my final year of engineering. To now back students chasing bold ideas, that's the most meaningful chapter of my career." Fund III will support up to 60 startups over the next four years, with initial investments ranging from INR 1 crore to INR 8 crore. Half of the fund is reserved for follow-on investments. Campus Fund's portfolio includes notable startups such as Digantara (space situational awareness), Sama (online dispute resolution), EtherealX (reusable rockets), and GreenGrahi (insect protein). Many have attracted follow-on capital from top firms like Accel, Peak XV Partners, Andreessen Horowitz, AlphaWave, and DST Global. The new fund is backed by a mix of family offices, institutions, and prominent individual investors, including 360 One. Notable limited partners include Kanwaljit Singh (Fireside Ventures), Bharat Shah (HDFC Bank co-founder), Asha Jadeja Motwani, Jaimin Bhatt, and Sameen Farooqui. Campus Fund continues to strengthen its position as a key catalyst for young founders shaping the future.
Yahoo
an hour ago
- Yahoo
Why OpenAI engineers are turning down $100 million from Meta, according to Sam Altman
When you buy through links on our articles, Future and its syndication partners may earn a commission. OpenAI CEO Sam Altman says competitors, particularly Mark Zuckerberg's Meta, have been trying to poach OpenAI engineers with sky-high compensation packages. 'They started making these, like, giant offers to people on our team. You know, like $100 million signing bonuses and more than that in compensation per year,' Altman said this week on the Uncapped podcast, hosted by his brother, Jack Altman. Altman said he was glad to see that those enticing offers haven't worked on OpenAI's best people. He assumes this is because they looked at the two paths, Meta and OpenAI, and concluded that the latter has a better shot at delivering on superintelligence and will eventually become the more valuable company. Amid the digs, Altman said Meta is missing the one thing that truly matters in AI: a culture of real innovation. 'There are many things I respect about Meta as a company, but I don't think they're great at innovation,' said Altman, when discussing Meta's attempts to lure OpenAI engineers. He explained that by trying to recruit OpenAI staff with massive guaranteed compensation packages, Meta is essentially building a culture that prioritizes money over the work and mission. He believes that focusing on money rather than purpose and product is a recipe for the wrong kind of culture. Altman contrasted this with OpenAI's approach, which he said attracts and retains talent by aligning financial incentives with a shared sense of purpose and innovative work. 'The special thing about OpenAI is we've managed to build a culture that is good at innovation, and I think we understand a lot of things they don't know about what it takes to succeed at that,' he explained further. Drawing a parallel to past tech rivalries, Altman recalled hearing Zuckerberg discuss how Google tried to enter the social media space in the early days of Facebook. However, to those at Facebook, it was clear that it wasn't going to work for Google. Altman said he now feels similarly about Meta's approach to AI, suggesting that Meta is making an error by trying to replicate OpenAI's success directly. He even discussed how he believes many people at Meta simply copy OpenAI. Altman explained this with an example of how many other companies' chat apps resemble ChatGPT, down to the UI mistakes. He drew from his own experience to argue that the copy-and-paste strategy is fundamentally flawed, and that trying to go where your competitor already is, instead of building a culture around innovation, rarely works. When asked why he thinks Meta sees OpenAI as such a competitor, Altman mentioned how an ex-Meta employee once told him that Meta views ChatGPT as a Facebook replacement. He explained that the user experience with ChatGPT felt different, like one of the few tech products that didn't feel 'somewhat adversarial.' He contrasted this with Google, which he said has started showing worse search results, and with Meta's products, which try to hack users' brains to keep them scrolling. Instead of doing either, ChatGPT simply tries to help users with whatever questions they may have, and even help them feel better. Beyond discussing Meta, the Altman brothers talked about a wide range of topics related to the future of AI, OpenAI's strategy, and even Sam's personal reflections. Altman made a 'crazy claim' that AI will discover new science, and that humanoid robots are one of his dreams — something he thinks will be achievable within the next 5 to 10 years. An internal OpenAI doc reveals exactly how ChatGPT may become your "super-assistant" very soon OpenAI CEO Sam Altman replies to artists irate over their stolen work ChatGPT's Sam Altman threatened to "Uno reverse" Facebook over AI app — he might be dead serious
